Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Deferred Revenue: 2023-2025

Historic Current Deferred Revenue for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to $351,000.

  • Entrada Therapeutics' Current Deferred Revenue fell 99.24% to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $351,000, marking a year-over-year decrease of 99.24%. This contributed to the annual value of $13.7 million for FY2024, which is 89.68% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Current Deferred Revenue stood at $351,000, which was down 49.06% from $689,000 recorded in Q2 2025.
  • Entrada Therapeutics' Current Deferred Revenue's 5-year high stood at $148.5 million during Q1 2024, with a 5-year trough of $351,000 in Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median Current Deferred Revenue value was $60.5 million (recorded in 2024), while the average stood at $70.5 million.
  • Per our database at Business Quant, Entrada Therapeutics' Current Deferred Revenue grew by 21.35% in 2024 and then slumped by 99.24% in 2025.
  • Over the past 3 years, Entrada Therapeutics' Current Deferred Revenue (Quarterly) stood at $132.3 million in 2023, then crashed by 89.68% to $13.7 million in 2024, then slumped by 99.24% to $351,000 in 2025.
  • Its last three reported values are $351,000 in Q3 2025, $689,000 for Q2 2025, and $1.4 million during Q1 2025.